MacroGenics, Inc.
MGNXMacroGenics, Inc. is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for cancer and autoimmune diseases. The company leverages its proprietary protein engineering platform to create targeted treatments aimed at enhancing immune responses and improving patient outcomes.
Company News
The global T-Cell Engagers market is projected to grow from USD 2.4 billion in 2024 to USD 18.8 billion by 2034, representing a 21.2% CAGR. The market is driven by advancements in precision-targeted therapies, wider clinical accessibility, and AI-enabled patient monitoring. Key players include Amgen, Genmab, Roche/Genentech, and others, with expa...
MacroGenics reported Q2 2025 financial results with revenue of $22.2 million, missing analyst expectations. The company is focusing on its research-stage pipeline and strategic partnerships while managing costs after exiting its previous marketed product.
Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.
The global immunotoxins market is projected to grow at a CAGR of 8.11% from 2024 to 2034, driven by the rising prevalence of malignancies, increased R&D, and the approval of new immunotoxin therapies. Diphtheria toxin-based immunotoxins lead revenue, while Pseudomonas exotoxins show rapid growth potential.
Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.
